Very early MRI responses to therapy as a predictor of later radiographic progression in early rheumatoid arthritis

Conaghan, Philip G.; Østergaard, Mikkel; Troum, Orrin; Bowes, Michael A.; Guillard, Gwenael; Wilkinson, Bethanie; Xie, Zhiyong; Andrews, John; Stein, Amy; Chapman, Douglass; Koenig, Andrew

Published in:
Arthritis Research and Therapy

DOI:
10.1186/s13075-019-2000-1

Publication date:
2019

Document version
Publisher's PDF, also known as Version of record

Document license:
CC BY

Citation for published version (APA):
Conaghan, P. G., Østergaard, M., Troum, O., Bowes, M. A., Guillard, G., Wilkinson, B., ... Koenig, A. (2019). Very early MRI responses to therapy as a predictor of later radiographic progression in early rheumatoid arthritis. Arthritis Research and Therapy, 21, [214]. https://doi.org/10.1186/s13075-019-2000-1
Very early MRI responses to therapy as a predictor of later radiographic progression in early rheumatoid arthritis

Philip G. Conaghan¹, Mikkel Østergaard², Orrin Troum³, Michael A. Bowes⁴, Gwenael Guillard⁴, Bethanie Wilkinson⁵, Zhiyong Xie⁵, John Andrews⁶, Amy Stein⁷, Douglass Chapman⁶ and Andrew Koenig⁸

Abstract

Background: The objective of this study was to evaluate early changes in magnetic resonance imaging (MRI) and clinical disease activity measures as predictors of later structural progression in early rheumatoid arthritis (RA).

Methods: This was a post hoc analysis of data pooled across treatments from a three-arm (tofacitinib monotherapy, tofacitinib with methotrexate [MTX], or MTX monotherapy) trial of MTX-naïve patients with early, active RA. Synovitis, osteitis and erosions were assessed with the Outcome Measures in Rheumatology (OMERACT) RA MRI scoring system (RAMRIS) and RAMRIQ (automated quantitative RA MRI assessment system; automated RAMRIS) at months 0, 1, 3, 6 and 12. Radiographs were assessed at months 0, 6 and 12, and clinical endpoints were assessed at all timepoints. Univariate and multivariate analyses explored the predictive value of early changes in RAMRIS/RAMRIQ parameters and disease activity measures, with respect to subsequent radiographic progression.

Results: Data from 109 patients with a mean RA duration of 0.7 years were included. In univariate analyses, changes in RAMRIS erosions at months 1 and 3 significantly predicted radiographic progression at month 12 (both \( p < 0.01 \)); changes in RAMRIQ synovitis and osteitis at months 1 and 3 were significant predictors of RAMRIS erosions and radiographic progression at month 12 (all \( p < 0.01 \)). In subsequent multivariate analyses, RAMRIS erosion change at month 1 (\( p < 0.05 \)) and RAMRIQ osteitis changes at months 1 and 3 (both \( p < 0.01 \)) were significant independent predictors of radiographic progression at month 12. Univariate analyses demonstrated that changes in Clinical Disease Activity Index (CDAI) and Disease Activity Score in 28 joints, erythrocyte sedimentation rate (DAS28-4[ESR]) at months 1 and 3 were not predictive of month 12 radiographic progression.

Conclusions: MRI changes seen as early as 1 month after RA treatment initiation have the potential to better predict long-term radiographic progression than changes in disease activity measures.

Keywords: Bone erosion, Disease activity, Joint space narrowing, Osteitis, Predictive ability, Radiographic progression, RAMRIS, RAMRIQ, Rheumatoid arthritis, Synovitis
Background

Rheumatoid arthritis (RA) has a substantial impact on patients, with joint inflammation resulting in pain and destruction of the joints, leading to reduced quality of life and substantial disability [1]. A treat-to-target approach is recommended in RA, with regular assessments and adjustment of treatment for inadequate response [2, 3]. Studies have demonstrated clinical response to therapy at months 1 to 3 to be predictive of longer-term achievement of clinical targets (decrease in Disease Activity Score in 28 joints, erythrocyte sedimentation rate [DAS28-4(ESR)] and Clinical Disease Activity Index [CDAI]) with conventional synthetic disease-modifying antirheumatic drugs (DMARDs) [4], biologic DMARDs [5] and the Janus kinase (JAK) inhibitor, baricitinib [6].

Magnetic resonance imaging (MRI) can assess inflammation (synovitis and bone marrow edema/osteitis) as well as damage (erosions) in joints, using the semi-quantitative Outcome Measures in Rheumatology (OMERACT) RA MRI scoring system (RAMRIS) [7, 8] and, more recently, the automated quantitative RA MRI assessment system (RAMRIQ; automated RAMRIS) [8, 9]. This sensitivity for pathology detection may provide a tool for accurate early detection of an objective treatment response.

Tofacitinib is an oral JAK inhibitor for the treatment of RA. In a phase 2 study of tofacitinib 10 mg twice daily (BID) with and without concomitant methotrexate (MTX), tofacitinib reduced inflammation and inhibited progression of structural damage from baseline to month 12 compared with treatment with MTX alone, as assessed using RAMRIS and RAMRIQ [8].

The aim of this post hoc analysis was therefore to evaluate early changes in MRI and clinical measures in this phase 2 study as predictors of later structural changes.

Methods

Study design and patients

This was a post hoc analysis of data from a 1-year, exploratory, phase 2, randomised, double-blind, parallel-group study (A3921068; NCT01164579). Full details of the study design and patient population have been reported previously [8]. Briefly, patients aged ≥ 18 years with active RA were randomised 1:1:1 to tofacitinib 10 mg BID monotherapy, tofacitinib 10 mg BID with MTX, or MTX monotherapy. Patients had RA of ≤ 2 years’ duration and 103/109 (94%) patients were MTX-naive. This study was approved by the Institutional Review Boards and/or Independent Ethics Committees at each investigational centre, and all patients provided written informed consent.

MRI and radiography

MRIs of unilateral wrist and metacarpophalangeal (MCP) joints were obtained at screening and months 1, 3, 6 and 12, and were used to assess synovitis, osteitis (bone marrow oedema) and erosions using RAMRIS [7] and RAMRIQ [9]. The hand that was most clinically affected at screening was chosen for MRI assessment throughout the study. If both hands were equally affected, the dominant hand was chosen. Radiographic progression was based on mean change from baseline in modified Total Sharp Scores (mTSS) [10], determined from radiographs at baseline, month 6 and month 12. The OMERACT RAMRIS semi-quantitatively assessed osteitis (using short-tau inversion recovery sequences), synovitis (using pre/post-contrast T1-weighted sequences) and bone erosions (using T1-weighted sequences) in three areas of the wrist and in MCP joints 1–5 [7], using a single, centralised reader, blinded to chronology and all clinical and imaging data. RAMRIQ is a fully automated quantitative measurement system (Imorphics, Manchester, UK) that assessed the same three pathologies as RAMRIS. For RAMRIQ assessments, the pre-contrast and post-contrast T1-weighted MRI sequences of the same joints and bones were used. The system is based on the accurate 3D segmentation of finger bones using a method based on statistical shape models that identify the whole bone in 3D and are therefore less susceptible to differences between readers and hand position in the MRI coil. Synovitis volume is the volume of the regions around the joint where the synovial capsule is found that enhances with contrast agent on T1-weighted images. Osteitis volume is the volume inside the bone that enhances with contrast agent on T1-weighted images. Finally, erosions are measured as the volume of bone (either the complete bone, or the bone within 15 mm of the joint [10 mm for RAMRIS] for longer bones) that is classified as ‘not healthy’ using a machine-vision classification method. RAMRIQ osteitis values were reported as normalised volume (%) calculated as (total volume osteitis/total bone volume) × 100, and RAMRIQ erosions values were also reported as normalised volume (%), calculated as (total volume eroded bone/total bone volume) × 100.

Disease activity

Disease activity endpoints were changes from baseline at months 1 and 3 in CDAI scores and DAS28-4(ESR).

Statistical methods and analysis

Analyses were on data pooled across treatment groups, given the sample size. Pooled analyses were performed, as reliable markers of RA progression should not differ in their predictive value across treatment groups; thus, pooled analyses allow for more generalisation.

Univariate linear regression analyses were used to assess the predictive value of changes in RAMRIS synovitis, osteitis and erosions from baseline to month 1 and, separately, from baseline to month 3, with respect to
Radiographic progression (mTSS) from baseline to month 12. Additionally, univariate linear regression analyses were used to assess the predictive value of changes in RAMRIQ synovitis, osteitis and erosions from baseline to month 1 and, separately, from baseline to month 3, with respect to changes in RAMRIS erosions and radiographic progression between baseline and month 12. Based on the results of the univariate analyses, we performed subsequent multivariate linear regression analyses of changes from baseline to month 1 and, separately, from baseline to month 3, with respect to radiographic progression from baseline to month 12, which included the RAMRIS and RAMRIQ variables that were shown to be statistically significant predictors in the univariate analyses. Univariate analyses were also used to assess the predictive value of changes in CDAI and DAS28-4(ESR) from baseline to month 1 and, separately, from baseline to month 3, with respect to radiographic progression from baseline to month 12. Statistical significance was considered to have been demonstrated with \( p \) values < 0.05; multiplicity was not adjusted for.

Results

Patients

Overall, 109 patients, 103 of whom were MTX-naïve, with mean ± standard deviation duration of RA of 0.7 ± 1.0 years were randomised, 36 to each tofacitinib 10 mg BID group (± MTX) and 37 to MTX monotherapy. Patient demographics and baseline disease characteristics have been reported previously and were generally well-balanced between treatment groups [8].

Radiographic progression

mTSS at baseline, month 6 and month 12, and least squares mean changes from baseline in mTSS at month 6 and month 12, are reported in Additional file 1.

Early RAMRIS changes as predictors of radiographic progression and joint space narrowing (JSN)

In univariate analyses, lower increases from baseline to both months 1 and 3 in RAMRIS erosions were significant predictors of less radiographic progression from baseline to month 12. Furthermore, lower increases from baseline to both months 1 and 3 in RAMRIS erosions significantly predicted less radiographic erosion from baseline to month 12, and lower increases from baseline to month 1 in RAMRIS erosions significantly predicted less JSN from baseline to month 12. No significant predictive value was observed between change from baseline to month 1 or 3 in RAMRIS synovitis or osteitis or between baseline and month 12 in radiographic progression, radiographic erosions, or JSN (Table 1).

Early RAMRIS changes as predictors of RAMRIS erosion progression and radiographic progression

In univariate analyses, lower increases from baseline to both months 1 and 3 in RAMRIS synovitis and osteitis were significant predictors of smaller changes in RAMRIS erosions from baseline to month 12. Lower changes from baseline to both months 1 and 3 in RAMRIS synovitis and osteitis (but not RAMRIS erosions) also significantly predicted less total radiographic progression (change in mTSS) and JSN progression between baseline and month 12 (Table 1).

Early changes in RAMRIS erosions and RAMRIQ synovitis and osteitis as predictors of radiographic progression

Baseline variables, including age, gender, race and smoking status, were not significant in univariate analyses (data not shown) and therefore were not included in the subsequent multivariate analyses. In multivariate analyses, the change in RAMRIS erosions from baseline to month 1, but not from baseline to month 3, was a significant independent predictor of total radiographic progression from baseline to month 12, and the changes in RAMRIS erosions from baseline to both months 1 and 3 were significant independent predictors of radiographic erosion progression from baseline to month 12 (Table 2). Furthermore, changes in RAMRIQ osteitis (but not RAMRIQ synovitis) at both months 1 and 3 were significant independent predictors of total and JSN radiographic progression from baseline to month 12, and the change in RAMRIQ synovitis at month 1, but not at month 3, was a significant independent predictor of radiographic erosion progression from baseline to month 12 (Table 2).

Early changes in disease activity as predictors of radiographic progression

In univariate analyses, there was no significant predictive value (\( p \) values > 0.05 for all analyses) of changes from baseline to month 1 or 3 in CDAI or DAS28-4(ESR) with respect to radiographic progression from baseline to month 12 (Additional file 2).

Discussion

Data from an RA clinical trial with a small number of patients, pooled across treatment groups, demonstrated that MRI assessment at months 1 and 3 after treatment initiation, using RAMRIS or the automated system RAMRIQ, generally predicted radiographic disease progression from baseline to month 12. Of the changes assessed, changes as early as month 1 in RAMRIQ synovitis and osteitis and in RAMRIS erosions were the best predictors of later disease progression. No predictive value was observed for concomitant changes from baseline to months 1 and 3 in the CDAI and DAS28-4(ESR) disease activity measures and later radiographic progression.
A number of studies have looked at baseline MRI features predicting outcome. An observational study of patients with RA of <1 year’s duration reported that RAMRIS-assessed osteitis at baseline was associated with radiographic progression at 1 year [11], and in a randomised controlled trial in patients with early RA, baseline osteitis assessed with RAMRIS was a strong predictor of radiographic progression after 2 years [12]. In terms of response prediction, in a clinical trial of golimumab in MTX-naïve patients with RA, multivariate logistic regression analysis of RAMRIS-assessed changes showed synovitis and osteitis at baseline and after 24 weeks of treatment predicted radiographic progression at 12 months, as did an increase in erosion of >0.5 at weeks 12 and 24; regression models incorporating baseline and 12- and 24-week changes in MRI measures of synovitis and osteitis improved the prediction of radiographic progression at 12 months above clinical disease activity measures [13]. However, we believe this to be the first report of MRI-detected changes as early as 1 month predicting radiographic progression after 12 months.

Given that it has been demonstrated that there is a window of opportunity in RA, an early predictor of disease progression at month 12 could allow treatment decisions to be made sooner, in line with the recommended treat-to-target approach in RA [2, 3]. The most effective early RA intervention will ideally lead to reduced long-term impact of the disease; thus, early identification of the likely long-term efficacy of treatment provides potential patient benefit [14]. Early prediction of longer-term

### Table 1

| Change from baseline to month 12 | RAMRIS synovitis | RAMRIS osteitis | RAMRIS erosions | RAMRIS synovitis | RAMRIS osteitis | RAMRIS erosions |
|----------------------------------|------------------|----------------|----------------|------------------|----------------|----------------|
| Total radiographic progression$^b$ | Estimate (SE); $p$ value | 0.044 (0.241); 0.856 | 0.007 (0.175); 0.971 | 1.431 (0.408); < 0.001 | 0.101 (0.188); 0.592 | −0.087 (0.138); 0.748 (0.252); 0.004 |
| Radiographic erosion progression | Estimate (SE); $p$ value | 0.039 (0.118); 0.743 | 0.031 (0.085); 0.718 | 0.638 (0.201); 0.002 | 0.087 (0.091); 0.339 | −0.013 (0.067); 0.853 < 0.001 |
| Radiographic JSN progression | Estimate (SE); $p$ value | 0.010 (0.163); 0.951 | −0.024 (0.118); 0.837 | 0.792 (0.284); 0.007 | 0.015 (0.127); 0.905 | −0.074 (0.093); 0.434 |

RAMRIS erosion progression

| Estimate (SE); $p$ value | 0.002 (0.0001); 0.004 | 0.287 (0.085); 0.001 | − | 0.0001 (0.0000); 0.008 | 0.354 (0.089); 0.001 |

Total radiographic progression$^b$

| Estimate (SE); $p$ value | 0.0004 (0.0001); < 0.001 | 0.930 (0.154); < 0.001 | 1.552 (0.846); 0.072 | 0.0002 (0.0001); 0.008 | 1.099 (0.222); < 0.001 | −0.498 (0.786); 0.529 |

Radiographic erosion progression

| Estimate (SE); $p$ value | 0.0001 (0.0000); 0.011 | 0.182 (0.092); 0.052 | 0.531 (0.417); 0.208 | 0.0001 (0.0000); 0.048 | 0.220 (0.123); 0.080 | −0.231 (0.382); 0.548 |

Radiographic JSN progression

| Estimate (SE); $p$ value | 0.0003 (0.0001); < 0.001 | 0.748 (0.089); < 0.001 | 1.017 (0.572); 0.080 | 0.0002 (0.0001); 0.012 | 0.879 (0.138); < 0.001 | −0.269 (0.533); 0.615 |

$^a$Based on univariate linear regression analysis

$^b$Assessed by mTSS

### Table 2

| Change from baseline to month 12 | RAMRIS synovitis | RAMRIS osteitis | RAMRIS erosions | RAMRIS synovitis | RAMRIS osteitis | RAMRIS erosions |
|----------------------------------|------------------|----------------|----------------|------------------|----------------|----------------|
| Total radiographic progression$^b$ | Estimate | 0.0002 | 0.645 | 0.777 | 0.0001 | 0.867 | 0.434 |
| $p$ value | 0.148 | 0.002 | 0.043 | 0.407 | 0.001 | 0.073 |
| Radiographic erosion progression | Estimate | 0.0001 | −0.043 | 0.590 | 0.0001 | −0.001 | 0.425 |
| $p$ value | 0.040 | 0.705 | 0.007 | 0.145 | 0.996 | 0.001 |
| Radiographic JSN progression | Estimate | 0.0000 | 0.688 | 0.187 | 0.0000 | 0.868 | 0.009 |
| $p$ value | 0.647 | < 0.001 | 0.409 | 0.907 | < 0.001 | 0.954 |

$^a$Based on univariate linear regression analysis

$^b$Assessed by mTSS

JSN joint space narrowing, MRI magnetic resonance imaging, mTSS modified Total Sharp Score, RA rheumatoid arthritis, RAMRIQ automated quantitative RA MRI assessment system, RAMRIS RA MRI scoring system
structural treatment benefit might also allow clinical trials of shorter duration and with more limited sample size, focused on structural changes, to be designed to assess new agents for the treatment of RA. Such trials would be preferable from the patient perspective and could also reduce drug development costs by rapidly assessing the clinical response to new therapies and reducing the need for additional imaging studies.

Early changes in disease activity, as measured with CDAI and DAS28-4(ESR), showed no significant predictive value for subsequent structural damage progression. Thus, the analyses presented here demonstrated that MRI assessment of structural changes during the first 3 months of treatment for RA, and even as early as 1 month, may better predict patients’ radiographically assessed response to treatment by month 12 than changes in clinical measures of disease activity in those 3 months. The MRI scoring procedures included here can be implemented using widely available MRI equipment (1.5-T scanners) and imaging sequences, as described previously [8].

A number of limitations of this study are acknowledged. The small sample size, post hoc nature of the analysis, single RAMRIS reader and lack of independence of the predictive parameters assessed all indicate a need for caution in the interpretation of findings. These analyses were exploratory in nature with the intent to determine which parameters had the strongest ability to predict treatment response. While this analysis, based on clinical trial data, demonstrated the utility of the RAMRIQ technique, the technology is still under development. Implementation in non-clinical-trial settings may be subject to variability due to potential variability in the implementation of the RAMRIS/RAMRIQ protocol across different magnetic field strengths, and possible inter-operator differences. Further exploration of this finding with other agents is warranted to evaluate the clinical implications.

Conclusions
In conclusion, incorporation of early MRI measurement in RA clinical trials will likely enable prediction of later response to treatment, allowing more rapid assessment of the efficacy of new medications. There is also the potential to use MRI as a biomarker to inform treatment decisions in clinical practice. However, the findings reported here require further validation.

Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.1186/s13075-019-2000-1.

Additional file 1: Descriptive statistics of mTSS and statistical analysis of change from baseline in mTSS over time.
Additional file 2: Univariate analyses* of predictive value of early changes in CDAI and DAS28-4(ESR) for later radiographic changes.

Abbreviations
BID: Twice daily; CDAI: Clinical Disease Activity Index; DAS28-4(ESR): Disease Activity Score in 28 joints, erythrocyte sedimentation rate; DMARD: Disease-modifying antirheumatic drug; JAK: Janus kinase; JSN: Joint space narrowing; MCP: Metacarpophalangeal; MRI: Magnetic resonance imaging; mTSS: Modified Total Sharp Scores; MTX: Methotrexate; OMERACT: Outcome Measures in Rheumatology; RAMRIQ: Automated quantitative RA MRI assessment system; RAMRIS: RA MRI scoring system; SE: Standard error

Acknowledgements
The authors would like to thank the patients, investigators and study teams involved in study A3921068.

PGC is supported in part by the UK National Institute for Health Research (NIHR) Leeds Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care.

Medical writing support, under the guidance of the authors, was provided by Daniel Binks, PhD, at CMC Connect, a division of McCann Health Medical Communications Ltd, Macclesfield, UK, and Carole Evans, PhD, on behalf of CMC Connect, and was funded by Pfizer Inc, New York, NY, USA, in accordance with Good Publication Practice (GPP3) guidelines (Ann Intern Med. 2015;163:461-4).

Authors’ contributions
PGC, MØ, OT, MAB, GG, BW, ZX, JA, AS, DC and AK were involved in the analysis and interpretation of data and drafting the article or revising it critically for important intellectual content, and all approved the final version to be submitted for publication. PGC had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. PGC, MØ, OT, BW and ZX were also involved in the study conception and design, and MAB and GG were involved in the acquisition of data.

Funding
This study was funded by Pfizer Inc. Pfizer authors participated in study design, analysis and interpretation of the data, and the writing of the manuscript.

Availability of data and materials
Up on request, and subject to certain criteria, conditions and exceptions (see https://www.pfizer.com/science/clinical-trials/trial-data-and-results for more information), Pfizer will provide access to individual de-identified participant data from Pfizer-sponsored global interventional clinical studies conducted for medicines, vaccines and medical devices (1) for indications that have been approved in the US and/or EU or (2) in programmes that have been terminated (i.e., development for all indications has been discontinued). Pfizer will also consider requests for the protocol, data dictionary, and statistical analysis plan. Data may be requested from Pfizer trials 24 months after study completion. The de-identified participant data will be made available to researchers whose proposals meet the research criteria and other conditions, and for which an exception does not apply, via a secure portal. To gain access, data requestors must enter into a data access agreement with Pfizer.

Ethics approval and consent to participate
This study was approved by the Institutional Review Boards and/ or Independent Ethics Committees at each investigational centre and all patients provided written informed consent.

Consent for publication
Not applicable.

Competing interests
PGC has been a consultant for AbbVie, Eli Lilly, Flexion, GlaxoSmithKline, Novartis, Pfizer Inc and Roche, and has been a member of the speakers’ bureau for AbbVie, Novartis and Roche. MØ has received grants or research support from AbbVie, Centocor and Merck, and has been a consultant and/or a member of the speakers’ bureau for AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Centocor, Eli Lilly, GlaxoSmithKline, Hospira, Janssen, Merck, Mundipharma, Novartis, Novo, Orion, Pfizer Inc, Regeneron, Roche, Schering-Plough, Takeda, UCB and Wyeth. OT has been a consultant for AbbVie, Aimgen, Bristol-Myers Squibb, Horizon, Lilly and Pfizer Inc, has
been a member of the speakers’ bureau for AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Horizon, Novartis, Pfizer Inc, Sanofi-Genzyme and Takeda, and has received grants or research support from AbbVie, Amgen, Bristol-Myers Squibb, Centocor, Corrona, Novartis and Pfizer Inc. MAB is an employee of Imomics Ltd, a wholly owned subsidiary of Stryker Corp, at the time the research was conducted. AS is an employee of IQVIA Inc and has acted as a paid consultant to Pfizer Inc in connection with analysis of study data. BW and AK were employees of Pfizer Inc at the time the research was conducted. ZX, JA and DC are employees and shareholders of Pfizer Inc.

Author details
1Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and UK National Institute for Health Research Leeds Biomedical Research Centre, Leeds, UK. 2Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, and Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark. 3Division of Rheumatology, University of Southern California Keck School of Medicine, Santa Monica, CA, USA. 4Imorphics Ltd, Worthington House, Towers Business Park, Manchester, UK. 5Pfizer Inc, Groton, CT, USA. 6Pfizer Inc, New York, NY, USA. 7Biostatistics Department, IQVIA Inc, Morrisville, NC, USA. 8Pfizer Inc, Collegeville, PA, USA.

Received: 1 May 2019 Accepted: 9 September 2019

References
1. van der Heijde D, Tanaka Y, Fleischmann R, Keystone E, Kremer J, Zerbini C, et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum. 2013;65:559–70.
2. Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Belkin RN, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2016;68:1–26.
3. Smolen JS, Landewé R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010;69:964–75.
4. White D, Pahau H, Duggan E, Paul S, Thomas R. Trajectory of intensive treat-to-target disease modifying drug regimen in an observational study of an early rheumatoid arthritis cohort. BMJ Open. 2013;3:e003083.
5. Skacelova S, Pavelka K, Chroust K. Early response to infliximab therapy predicts long-term disease activity outcomes in patients with rheumatoid arthritis: results from the Czech National Biological Therapy Registry (ATTRA). Ann Rheum Dis. 2013;71(Suppl 3):abstract SAT0153.
6. Kremer J, Dougados M, Genovese MC, Emery P, Yang L, de Bono S, et al. Response to tocilizumab at 4 weeks predicts response at 12 and 24 weeks in patients with rheumatoid arthritis: results from two phase 3 studies. Arthritis Rheumatol. 2015;67(Suppl 10):abstract 1050.
7. Østergaard M, Peterfy C, Conaghan P, McQueen F, Bird P, Ejbjerg B, et al. OMERACT Rheumatoid Arthritis Magnetic Resonance Imaging Studies. Core set of MRI acquisitions, joint pathology definitions, and the OMERACT RA-MRI scoring system. J Rheumatol. 2003;30:1385–6.
8. Conaghan PG, Østergaard M, Bowes MA, Wu C, Fuest T, van der Heijde D, et al. Comparing the effects of tocilizumab, methotrexate and the combination, on bone marrow oedema, synovitis and bone erosion in methotrexate-naive, early active rheumatoid arthritis: results of an exploratory randomised MRI study incorporating semiquantitative and quantitative techniques. Ann Rheum Dis. 2016;75:1024–33.
9. Bowes MA, Guillard G, Gill E, Vincent GR, Hensor E, Freeston JE, et al. Novel quantification of MRI provides a more sensitive outcome measure than Ramirs. Arthritis Rheumatol. 2014;66(Suppl 10):abstract 1178.
10. van der Heijde D, Simon L, Smolen J, Strand V, Sharp J, Boers M, et al. How to report radiographic data in randomized clinical trials in rheumatoid arthritis: guidelines from a roundtable discussion. Arthritis Rheum. 2002;47:215–8.
11. Haavardsholm EA, Bøyesen P, Østergaard M, Schildvold A, Kvien TK. Magnetic resonance imaging findings in 84 patients with early rheumatoid arthritis: bone marrow oedema predicts erosive progression. Ann Rheum Dis. 2008;67:794–800.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions